How Do Mild, Moderate, and Severe Hemophilia A Differ?
At a Glance
Hemophilia A severity is based on untreated baseline Factor VIII activity: mild is more than 5% through 40%, moderate is 1% through 5%, and severe is below 1%. Bleeding history and treatment also matter, so your hematology team should interpret your results.
When a doctor describes your Hemophilia A as “mild,” “moderate,” or “severe,” they are classifying the condition based on your baseline Factor VIII activity—the amount of active clotting protein in your blood when you are not currently receiving replacement treatment [1][2]. Your blood needs this protein to form a stable clot. Generally, the lower your baseline factor level, the harder it is for your body to stop bleeding without treatment.
It is important to remember that these categories describe typical untreated patterns. Effective preventive treatment can significantly reduce how often you bleed, meaning your day-to-day experience may not match the untreated descriptions below. Laboratory tests can also be affected by recent treatments, so a single test should be interpreted by your hematology team (your blood-disorder specialist team) [1].
Medical professionals classify Hemophilia A into three severity categories based on the percentage of normal Factor VIII activity in your blood [1][3]:
Mild Hemophilia A (Greater than 5% up to 40% Factor VIII Activity)
If you have mild hemophilia, you have low or reduced Factor VIII activity. People with mild hemophilia rarely experience major spontaneous bleeding (bleeding without a clear cause) [3]. For everyday activities, your risk of a sudden bleed is low but not zero. In fact, many individuals are not diagnosed until they experience prolonged bleeding after a significant injury, a dental extraction, or a surgery [4]. However, this does not mean the condition is harmless; serious injuries or surgeries still require careful medical management and advance planning to prevent dangerous bleeding [3].
Moderate Hemophilia A (1% to 5% Factor VIII Activity)
Moderate hemophilia sits in the middle of the spectrum [1]. People with moderate hemophilia may occasionally experience spontaneous bleeding, but this is less predictable and less frequent than in severe cases. However, significant bleeding after an injury, trauma, or surgical procedure can be substantial [4]. Depending on their personal bleeding history, some individuals with moderate hemophilia may also benefit from regular preventive treatment to protect their joints.
Severe Hemophilia A (Less than 1% Factor VIII Activity)
In severe Hemophilia A, there is almost no active Factor VIII in the blood [2]. Without treatment, this classification is typically associated with frequent, spontaneous bleeds into the joints and muscles, which often begin in early childhood [5][6]. A joint bleed may cause warmth, swelling, tightness, pain, or reduced movement. Because untreated spontaneous bleeding is common, most people with severe hemophilia are offered regular preventive treatment (prophylaxis) [5]. This might involve replacing the missing factor or using other specialized medications to prevent bleeds, depending on your individual needs and whether you have developed inhibitors (antibodies that stop Factor VIII from working).
The Numbers Aren’t Everything
While these percentages are the standard way doctors classify hemophilia, the label alone doesn’t perfectly predict your experience. Research shows that two people with the exact same Factor VIII activity level can have very different bleeding patterns [7][8]. Generally, higher factor levels correspond to fewer joint bleeds [9]. However, your personal bleeding history is just as important as your lab results.
Because of this individual variation, any upcoming dental work, surgery, or major procedure requires personalized planning with your hematology team [10][11]. Your doctors will look at your specific Factor VIII levels, your personal history of bleeding, and the type of procedure to create a customized plan to keep you safe [12].
🚨 Emergency Action Guidance
If you experience symptoms of a serious bleed—such as a head injury, sudden painful swelling or warmth in a joint or muscle, severe abdominal pain, or bleeding that won’t stop—do not wait to see if it gets worse. Follow your individualized emergency plan or contact your hemophilia treatment center or emergency services immediately. Never delay care to wait for lab confirmation of a bleed.
Common questions in this guide
What Factor VIII levels define mild, moderate, and severe Hemophilia A?
Can mild or moderate Hemophilia A cause serious bleeding?
Does severe Hemophilia A always cause frequent bleeding?
Why can two people with the same Factor VIII level bleed differently?
When should someone with Hemophilia A seek emergency care?
What are Factor VIII inhibitors, and why do they matter?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Severity categories
How would my Factor VIII activity level be used to classify my hemophilia as mild, moderate, or severe?
Planning for procedures
How would my hematology team plan for dental work or surgery to prevent bleeding?
Preventive treatment
What preventive options, such as replacing the missing factor, would fit my individual needs?
Related questions
Show more
Get notified when new evidence is published on Hemophilia A.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Desmopressin in moderate hemophilia A patients: a treatment worth considering.
Loomans JI, Kruip MJHA, Carcao M, et al.
Haematologica 2018; (103(3)):550-557 doi:10.3324/haematol.2017.180059.
PMID: 29305412 - 2
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
Ozelo MC, Mahlangu J, Pasi KJ, et al.
The New England journal of medicine 2022; (386(11)):1013-1025 doi:10.1056/NEJMoa2113708.
PMID: 35294811 - 3
The factor VIII treatment history of non-severe hemophilia A.
Abdi A, Kloosterman FR, Eckhardt CL, et al.
Journal of thrombosis and haemostasis : JTH 2020; (18(12)):3203-3210 doi:10.1111/jth.15076.
PMID: 32877570 - 4
Postoperative bleeding complicated by hemophilia A following anal fistula surgery: A case report.
Chen X, Tian R, Chen Z, et al.
Medicine 2025; (104(40)):e44962 doi:10.1097/MD.0000000000044962.
PMID: 41054107 - 5
Real-world provider experiences with hemophilia A gene therapy: administration of valoctocogene roxaparvovec.
Peyvandi F, Klamroth R, Oldenburg J, et al.
Research and practice in thrombosis and haemostasis 2026; (10(4)):106626 doi:10.1016/j.rpth.2026.106626.
PMID: 42232249 - 6
Congenital hemophilia A with low activity of factor XII: a case report and literature review.
Lei B, Liang C, Feng H
Italian journal of pediatrics 2021; (47(1)):204 doi:10.1186/s13052-021-01137-x.
PMID: 34635150 - 7
Phenotypic variation in severe hemophilia A is related to endogenous thrombin potential and plasma levels of factor VII.
Chaves DG, Fonseca FML, Araújo HCB, et al.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2022; (33(8)):463-467 doi:10.1097/MBC.0000000000001176.
PMID: 36409923 - 8
Patients with moderate hemophilia A and B with a severe bleeding phenotype have an increased burden of disease.
Verhagen MJA, van Balen EC, Blijlevens NMA, et al.
Journal of thrombosis and haemostasis : JTH 2024; (22(1)):152-162 doi:10.1016/j.jtha.2023.09.029.
PMID: 37813197 - 9
Bleeding phenotype according to factor level in 825 children with nonsevere hemophilia: data from the PedNet cohort.
de Kovel MS, Escuriola-Ettingshausen C, Königs C, et al.
Journal of thrombosis and haemostasis : JTH 2024; (22(9)):2460-2469 doi:10.1016/j.jtha.2024.05.030.
PMID: 38866249 - 10
Safe Outpatient Dental Management of a Pediatric Patient With Mild Hemophilia A: A Case Report.
Curiel-Ventura M, Torre-Delgadillo G, Alejandri-Gamboa V, et al.
Cureus 2025; (17(11)):e97254 doi:10.7759/cureus.97254.
PMID: 41426921 - 11
Minimally invasive coronary artery bypass grafting via a left lateral mini-thoracotomy in severe hemophilia A: a case report.
Hosoyama K, Yamada-Fujiwara M, Itagaki K, et al.
General thoracic and cardiovascular surgery cases 2026; (5(1)).
PMID: 41923266 - 12
Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trial.
Quon DV, Wang JD, Wang M, et al.
Therapeutic advances in hematology 2024; (15()):20406207241304645 doi:10.1177/20406207241304645.
PMID: 39712873
This page is for informational purposes only and does not constitute medical advice. Your hematology team should interpret your Factor VIII results and guide care for bleeding, procedures, and emergencies.